[Open innovation and licensing in the pharmaceutical industry]

[Article in Japanese]

Affiliations

Review

[Article in Japanese]

Motohiro Yamasaki. Nihon Yakurigaku Zasshi. 2013 Jul.

. 2013 Jul;142(1):28-31.

doi: 10.1254/fpj.142.28.

No abstract available

Similar articles

[Open innovation: public-private partnerships in pharmaceutical R&D].
Uchibayashi N. Uchibayashi N. Nihon Yakurigaku Zasshi. 2013 Jul;142(1):32-8. doi: 10.1254/fpj.142.32. Nihon Yakurigaku Zasshi. 2013. PMID: 23842226 Japanese. No abstract available.
[Change the world through business partnering - commercialization of biotechnology and open-innovation].
Tsukamoto Y. Tsukamoto Y. Nihon Yakurigaku Zasshi. 2013 May;141(5):268-74. doi: 10.1254/fpj.141.268. Nihon Yakurigaku Zasshi. 2013. PMID: 23665558 Review. Japanese. No abstract available.
[Requirements for the license-out of drug candidates to pharmaceutical companies].
Tawara S, Kobayashi N, Arai H, Masumi S, Itoh S, Nakahara Y, Morimoto N, Itano Y, Yamaguchi T, Niwa K, Seki J, Nakamura K. Tawara S, et al. Nihon Yakurigaku Zasshi. 2014 Apr;143(4):198-202. doi: 10.1254/fpj.143.198. Nihon Yakurigaku Zasshi. 2014. PMID: 24717609 Review. Japanese. No abstract available.
[Open innovation for Japanese pharmaceutical companies].
Hoshino T. Hoshino T. Nihon Yakurigaku Zasshi. 2013 Oct;142(4):184-9. doi: 10.1254/fpj.142.184. Nihon Yakurigaku Zasshi. 2013. PMID: 24107523 Japanese. No abstract available.
Q&A: Bernard Munos.
Bender E. Bender E. Nature. 2016 May 12;533(7602):S59. doi: 10.1038/533S59a. Nature. 2016. PMID: 27167392 No abstract available.